stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 0.00 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (9.24) | (3.90) | |
P/B ratio |
— | — | 0.00 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 0.00 | 0.00 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.90) | (1.04) | |
EV/FCF |
— | — | (1.90) | (1.04) | |
Quick Ratio |
0.29 | 0.51 | 0.35 | 0.39 | |
Current Ratio |
0.65 | 0.65 | 0.51 | 0.66 | |
Net Debt/EBITDA |
0.32 | 1.34 | 1.20 | 0.55 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.50 | 0.92 | 0.69 | 1.01 | |
Interest Coverage |
(1,914.25) | (44.94) | (16.55) | (30.27) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 2,197.86% | 2,480.99% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 8,375.40% | 8,940.91% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2,679.14% | 2,028.93% | |
Graham Net Nets |
— | — | (0.25) | (0.17) | |
Graham Number |
— | — | 52.07 | 16.80 | |
Earnings Yield |
— | — | (71.94%) | (118.97%) | |
Free Cash Flow Yield |
— | — | (43.70%) | (80.90%) | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.04 | |
Operating CF per Share |
(2.55) | (5.14) | (3.05) | (4.12) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.55) | (5.14) | (3.05) | (4.12) | |
Cash per Share |
1.60 | 8.23 | 5.04 | 2.73 | |
Shareholders Equity per Share |
0.13 | (3.98) | (5.94) | (0.66) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.13 | (3.98) | (5.94) | (0.66) | |
Free Cash Flow |
(1.15) | (2.37) | (1.43) | (2.29) | |
Working Capital |
(0.89) | (2.57) | (3.32) | (1.33) | |
Net Current Asset Value |
(0.89) | (2.57) | (3.32) | (1.54) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.57 | 0.52 | 0.38 | 0.75 | |
Average Assets |
1.33 | 5.88 | 4.46 | 3.84 | |
Average Common Equity |
(2.85) | 1.17 | 0.14 | 0.49 |
Columns are period end dates